Lucideon is hosting a free webinar titled ‘Update on USP Tests for Elemental Impurities – Are you ready?’ on Tuesday 7 June at 3PM (UK time) 10AM (EST).
The Heavy Metals limit test, as defined in USP <231>, is being removed after more than a century in use. The chapter will be officially replaced on 1 January 2018 but can be implemented now. This webinar will focus on how the new chapter will affect businesses and the benefits of implementing USP <232> before the mandatory switch at the start of 2018. There will also be attention given to some of the analytical challenges posed by USP <233> - a chapter that defines the methods for analysing the limits given in USP <232>.
Craig Donald, Head of Chemistry, Lucideon, said:
“The elemental limits for Heavy Metals have been evaluated and the changes were published in December 2015. These changes include the creation of different classes of toxicity for sets of heavy metal elements. The accompanying test methods in USP <233> reflect the new classifications but also mean some significant changes to current practices for determining levels of toxic metals in pharmaceutical products.”
“Although the new chapter doesn’t require implementation until 1 January 2018 we would encourage action sooner rather than later. The webinar has been designed to highlight some of the main areas for consideration within the new chapters and the advantages of acting before they become mandatory in 2018.”
Lucideon provides pharmaceutical testing and analysis through a team of experts and state-of-the-art pharmaceutical laboratories. Lucideon’s experts also provide consultancy to the pharmaceutical industry and have studied the new chapters in great detail to ascertain how the changes will affect businesses and the best way for the transition to be made with minimum disruption.
Lucideon’s pharmaceutical services also include: quality control, powder consultancy, failure analysis, method development, cleaning validation, stability storage and testing, including accelerated ageing and microbiology testing. Materials technology developments include inorganic controlled release technology platforms for applications such as drug abuse deterrence.
To register for the webinar visit www.lucideon.com/usp-webinar
-ends-
About Lucideon
Lucideon is a leading international provider of materials development, testing and assurance.
The company aims to improve the competitive advantage and profitability of its clients by providing them with the expertise, accurate results and objective, innovative thinking that they need to optimise their materials, products, processes, systems and businesses.
Through its offices and laboratories in the UK, US and the Far East, Lucideon provides materials and assurance expertise to clients in a wide range of sectors, including healthcare, construction, ceramics and power generation.
The Heavy Metals limit test, as defined in USP <231>, is being removed after more than a century in use. The chapter will be officially replaced on 1 January 2018 but can be implemented now. This webinar will focus on how the new chapter will affect businesses and the benefits of implementing USP <232> before the mandatory switch at the start of 2018. There will also be attention given to some of the analytical challenges posed by USP <233> - a chapter that defines the methods for analysing the limits given in USP <232>.
Craig Donald, Head of Chemistry, Lucideon, said:
“The elemental limits for Heavy Metals have been evaluated and the changes were published in December 2015. These changes include the creation of different classes of toxicity for sets of heavy metal elements. The accompanying test methods in USP <233> reflect the new classifications but also mean some significant changes to current practices for determining levels of toxic metals in pharmaceutical products.”
“Although the new chapter doesn’t require implementation until 1 January 2018 we would encourage action sooner rather than later. The webinar has been designed to highlight some of the main areas for consideration within the new chapters and the advantages of acting before they become mandatory in 2018.”
Lucideon provides pharmaceutical testing and analysis through a team of experts and state-of-the-art pharmaceutical laboratories. Lucideon’s experts also provide consultancy to the pharmaceutical industry and have studied the new chapters in great detail to ascertain how the changes will affect businesses and the best way for the transition to be made with minimum disruption.
Lucideon’s pharmaceutical services also include: quality control, powder consultancy, failure analysis, method development, cleaning validation, stability storage and testing, including accelerated ageing and microbiology testing. Materials technology developments include inorganic controlled release technology platforms for applications such as drug abuse deterrence.
To register for the webinar visit www.lucideon.com/usp-webinar
-ends-
About Lucideon
Lucideon is a leading international provider of materials development, testing and assurance.
The company aims to improve the competitive advantage and profitability of its clients by providing them with the expertise, accurate results and objective, innovative thinking that they need to optimise their materials, products, processes, systems and businesses.
Through its offices and laboratories in the UK, US and the Far East, Lucideon provides materials and assurance expertise to clients in a wide range of sectors, including healthcare, construction, ceramics and power generation.
